Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALO212
- Development stage
- Preclinical
- Lead developer
- Compass Biomedical
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
ALO212 is an allogeneic stem cell therapy derived from umbilical cord blood, currently under development by Compass Biomedical (formerly Arteriocyte, Inc.). Classified as a cell replacement therapy, it is specifically designed for the treatment of cardiovascular diseases, with a primary focus on critical limb ischemia (CLI). The therapy aims to promote angiogenesis and facilitate tissue repair in patients suffering from severe peripheral artery disease. As of the latest reports, the development status of ALO212 is listed as pending, indicating it is in the early research or preclinical stages and has not yet received regulatory approval.
Beyond the preview
Go deeper on ALO212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALO212.